Posterior cortical atrophy: the value of neuroimaging in assessing memory loss
Letter to the Editor

Posterior cortical atrophy: the value of neuroimaging in assessing memory loss

Stefanos Ioannidis1, Helam Roseman1, Kenneth Chan1, Stephane Duckett1, Ruth Mizoguchi1,2

1Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK; 2Health Services for Elderly People, Royal Free Hospital, London, UK

Correspondence to: Ruth Mizoguchi. Health Services for Elderly People, Royal Free Hospital, Pond Street Hampstead, London NW3 2QG, UK. Email: ruth.mizoguchi@nhs.net.

Submitted Jul 30, 2017. Accepted for publication Sep 02, 2017.

doi: 10.21037/qims.2017.09.04


Introduction

Posterior cortical atrophy (PCA) is a clinico-radiologic syndrome characterized by progressive decline in visual processing skills (1). Although PCA is regarded as a subgroup of Alzheimer’s disease (AD), it is associated with the following “atypical” features which differentiate it from AD including: (I) younger age at onset of 50–65 years; (II) topographic distributions of atrophy and decreased metabolic activity in the posterior cortex (2,3).

The prevalence and incidence of PCA remains currently unknown (4). However, a study by Snowden and colleagues showed that out of 523 patients presenting with AD, 24 (5%) had a visual presentation, and 13 (3%) had an apraxic presentation was labelled as PCA (4,5).

Pathologically, a study by Levine and co-workers showed a higher density of senile plaques and neurofibrillary tangles in the posterior cortex of PCA patients (6). In another study, Tang-Wai and co-workers showed that when compared to typical AD, PCA specimens have a higher density of neurofibrillary tangles in visual cortices and a lower density in the hippocampus and subiculum (7).

We present a case of old age onset PCA with an atypical presentation: visual symptoms were subtle initially compared to the degree of memory loss, which made differentiation from AD more challenging. Neuroimaging findings in combination with neuropsychometric evaluation were crucial in making the diagnosis of this atypical presentation of PCA.


Case presentation

An 81-year-old right-handed man with formal education of 14 years presented to the memory clinic with 9-month history of episodic memory loss. He also reported concurrent difficulty in locating objects in his living environment and increasing use of reminder notes. Aside from his cognitive impairment, he mentioned recent visual decline such as inability to judge depth on staircases which led to recurrent falls. He was also involved in a collision with a vehicle while crossing the road due to his poor visual judgement. Nevertheless, he retained his ability to read, albeit relying on newspapers with contextual cues such as colorful illustrations. He denied visual hallucination as part of assessing for Behavioral and Psychological symptoms of Dementia (BPSD). There was report of visual illusions relating to distance of position, e.g., furniture in his room alternating far and close and not relating to one another.

His past medical history included ischemic heart disease, hypertension and a transient ischemic attack. There were no relevant medication history and no family history of dementia. He was an ex-smoker with previous excess alcohol intake and remained independent in activities of daily living.

He was initially investigated with a blood panel including full blood count, renal and liver function, bone profile, thyroid function, and hematinics which were all within normal limits.

An ophthalmology assessment was performed which did not identify a cause for his visual complaints. His cognitive decline was reflected in the Addenbrooke’s Cognitive Examination III (ACE III 52/100) with core deficit in memory and verbal fluency. In addition to his memory impairment, neurological examination and further comprehensive neuropsychometric evaluation revealed optic ataxia, simultanagnosia, as well as visuospatial and visuoperceptual impairment as demonstrated in the Rey complex figure test (Figure 1).

Figure 1 Visuo-spatial and visuo-perceptual impairment: patient drawings showing a deficit in visual processing (top) and in the Rey complex figure (bottom).

Contrast enhanced computed tomography (CT) head revealed posterior parietal lobe atrophy with preserved hippocampus (Figure 2A). Fluorodeoxyglucose-positron emission tomography (FDG-PET) revealed reduction of FDG uptake in the posterior cortex (Figure 2B) in keeping with a diagnosis of PCA.

Figure 2 Cross-sectional intracranial imaging showing involution of the posterior parietal lobes bilaterally (red arrows) on CT head (A), and reduced FDG-PET uptake (white arrows) in the posterior cortex (B). CT, computed tomography; FDG-PET, fluorodeoxyglucose-positron emission tomography.

In a patient with an insidious onset of cognitive impairment, AD is most commonly considered. However, the patient’s unusual pattern of visual performance raised the possibility of (I) PCA and (II) mixed type dementia with static and progressive elements such as having a traumatic insult. There was no evidence of traumatic head injury either from the history or on neuro-imaging. A diagnosis of PCA was made based on the clinical presentation, neuroimaging and neuropsychological assessment.

Treatment with an acetylcholinesterase inhibitor (donepezil, 10 mg/day) was initiated which preserved his cognition a year later as reflected on subsequent ACE III. He was referred to PCA support groups. He had a comprehensive assessment by occupational therapy and adjustments were made to his home environment to aid in perceptual activities.


Discussion

Case reports to date have described the visual and spatial decline in PCA patients that precedes the memory loss (8,9). In this case, the patient had presented with memory problems, despite ongoing visual deficits that were occurring concurrently. Patients often develop a compensatory strategy with the visual deficit until disabling cognitive difficulties take hold. The presence of PCA is subsequently unmasked when they seek medical opinion and undergo detailed memory and neuro-psychometric evaluation. In elderly patients presenting with impaired memory, the diagnosis of PCA needs to be considered.

Crutch et al. have suggested a consensus on the three-level diagnostic criteria for PCA, whereby PCA diagnosis is made in level 1, with further subtyping in levels 2 and 3 in the presence of co-existing neurodegenerative disorders (e.g., dementia with Lewy bodies, corticobasal degeneration) (1). The patient met the level 1 diagnostic criteria—clinical: insidious onset, gradual progression and visual deficit; cognitive: evidenced in the neuropsychology work up; radiological: evidenced in the CT and PET scans. It was not deemed that the patient fulfilled the diagnostic criteria for an additional disease process and he was therefore classified as level 2, PCA-pure.

Although most studies have shown age at onset in mid 50s to early 60s, a limited number of studies have reported a broader age range of 61.1±7.8 and 60±8.9 years (7,10). The emphasis on age as part of the diagnostic picture may inadvertently exclude older patients given that younger, working age patients are more likely to be acutely aware of visual problems and thus present earlier to physicians. PCA may, therefore be more common in older adults than previously thought.


Conclusions

  • PCA may be more common in older adults than previously suspected and has to be considered for older patients presenting with memory loss;
  • A thorough history together with a radiological workup and neuropsychological assessment can elude to this disease subtype;
  • Including a PET scan in the workup of a suspected PCA case can support the diagnosis as impaired glucose metabolism affects the posterior cerebral hemispheres in PCA when compared to control subjects (11);
  • Correctly identifying the disease subtype is crucial for patient management including provision of help in perceptual activities.

Acknowledgements

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Informed Consent: Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.


References

  1. Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, Dickerson BC, Vandenberghe R, Ahmed S, Bak TH, Boeve BF, Butler C, Cappa SF, Ceccaldi M, de Souza LC, Dubois B, Felician O, Galasko D, Graff-Radford J, Graff-Radford NR, Hof PR, Krolak-Salmon P, Lehmann M, Magnin E, Mendez MF, Nestor PJ, Onyike CU, Pelak VS, Pijnenburg Y, Primativo S, Rossor MN, Ryan NS, Scheltens P, Shakespeare TJ, Suárez González A, Tang-Wai DF, Yong KX, Carrillo M, Fox NC. Alzheimer's Association ISTAART Atypical Alzheimer's Disease and Associated Syndromes Professional Interest Area. Consensus classification of posterior cortical atrophy. Alzheimers Dement 2017;13:870-84. [Crossref] [PubMed]
  2. Crutch SJ, Schott JM, Rabinovici GD, Boeve BF, Cappa SF, Dickerson BC, Dubois B, Graff-Radford NR, Krolak-Salmon P, Lehmann M, Mendez MF, Pijnenburg Y, Ryan NS, Scheltens P, Shakespeare T, Tang-Wai DF, van der Flier WM, Bain L, Carrillo MC, Fox NC. Shining a light on posterior cortical atrophy. Alzheimers Dement 2013;9:463-5. [Crossref] [PubMed]
  3. Borruat FX. Posterior cortical atrophy: review of the recent literature. Curr Neurol Neurosci Rep 2013;13:406. [Crossref] [PubMed]
  4. Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol 2012;11:170-8. [Crossref] [PubMed]
  5. Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, Pritchard A, Lendon CL, Richardson AM, Varma A, Neary D, Mann D. Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex 2007;43:835-45. [Crossref] [PubMed]
  6. Levine DN, Lee JM, Fisher CM. The visual variant of Alzheimer's disease: a clinicopathologic case study. Neurology 1993;43:305-13. [Crossref] [PubMed]
  7. Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, Caselli RJ, Knopman DS, Petersen RC. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004;63:1168-74. [Crossref] [PubMed]
  8. Marques IB, Tábuas-Pereira M, Milheiro M, Santana I. Biparietal variant of Alzheimer's disease: a rare presentation of a common disease. BMJ Case Rep 2015.bcr2014207011. [Crossref] [PubMed]
  9. Müller KI, Bekkelund SI. Visual impairment and posterior cortical atrophy preceding rapid progressive dementia. BMJ Case Rep 2013.bcr2012007624. [PubMed]
  10. Kas A, de Souza LC, Samri D, Bartolomeo P, Lacomblez L, Kalafat M, Migliaccio R, Thiebaut de Schotten M, Cohen L, Dubois B, Habert MO, Sarazin M. Neural correlates of cognitive impairment in posterior cortical atrophy. Brain 2011;134:1464-78. [Crossref] [PubMed]
  11. Nestor PJ, Caine D, Fryer TD, Clarke J, Hodges JR. The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDG-PET. J Neurol Neurosurg Psychiatry 2003;74:1521-9. [Crossref] [PubMed]
Cite this article as: Ioannidis S, Roseman H, Chan K, Duckett S, Mizoguchi R. Posterior cortical atrophy: the value of neuroimaging in assessing memory loss. Quant Imaging Med Surg 2017;7(6):736-739. doi: 10.21037/qims.2017.09.04

Refbacks

  • There are currently no refbacks.